title: Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension.
abstract: Clinical trials demonstrated that a fixed-dose combination (FDC) of the beta-blocker nebivolol (5 mg) and the angiotensin II antagonist valsartan (80 mg) produced a significant reduction of both diastolic and systolic blood pressure in patients with hypertension. Both nebivolol and valsartan contributed to this effect, partial additivity of 86.6% and 82.2% being observed for diastolic and systolic blood pressure, respectively. These values are very similar to the additivity ratios of other recently approved FDCs for hypertension. Use of the FDC nebivolol 5 mg/valsartan 80 mg formulation was associated with a low incidence of treatment-related adverse effects and of serious adverse effects. There was no evidence of adverse effects due to beta2-adrenoceptor blockade. The FDC (Byvalson) was approved and launched in 2016 in the U.S. for the treatment of hypertension.
authors.affiliation: University of Auckland School of Medical Sciences, Pharmacology & Clinical Pharmacology Auckland, New Zealand. dmpaton38@yahoo.ca.
authors.forename: D M
authors.initials: DM
authors.lastname: Paton
mesh_terms: D058665:Adrenergic beta-1 Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001794:Blood Pressure / Q000187:drug effects*; D017277:Drug Approval; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000068577:Nebivolol / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D000068756:Valsartan / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D058665:Adrenergic beta-1 Receptor Agonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D004338:Drug Combinations; D014665:Vasodilator Agents; D000068577:Nebivolol; D000068756:Valsartan
keywords: Fixed-dose combination; Hypertension; Nebivolol; Valsartan